Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer

Archives of Surgery

Volumn 146, Issue 1, 2011, Pages 26-33

  Mailey, Brian ^a   Artinyan, Avo ^a   Khalili, Joshua ^a   Denitz, Jordan ^a   Sanchez Luege, Nicelio ^a   Sun, Can Lan ^a,b   Bhatia, Smita ^a,b   Nissen, Nicholas ^c   Colquhoun, Steven D ^c   Kim, Joseph ^a,b  

^a City of Hope ^*  (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 78751687115     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2010.295     Document Type: Article

References (42)

1. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-3230.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-156.
3. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-65.
4. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7(1):26-34.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.
6. Takenaka K, Yamamoto K, Taketomi A, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology. 1995;22(1):20-24.
7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181-200.
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.
9. Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008;2(1):81-92.
10. Chen M-S, Li J-Q, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321-328.
11. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19(3):311-322.
12. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100(12):2708-2716.
13. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl. 2004;10(7):886-897.
14. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534-540.
15. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17(1):324-331.
16. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143(2):182-188.
17. Heimbach JK. Liver transplantation for hepatocellular carcinoma. Cancer J. 2008;14(2):95-99.
18. Andorno E, Bottino G, Morelli N, et al. Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis. Transplant Proc. 2008;40(6):1972-1973.
19. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-1403.
20. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956;8(2):174.
21. Abelev GI, Assecritova IV, Kraevsky NA, Perova SD, Perevodchikova NI. Embryonal serum alpha-globulin in cancer patients: diagnostic value. Int J Cancer. 1967;2(5):551-558.
22. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alphafetoprotein levels. J Clin Gastroenterol. 2000;31(4):302-308.
23. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990;12(6):1420-1432.
24. Kew MC. Tumour markers of hepatocellular carcinoma. J Gastroenterol Hepatol. 1989;4(4):373-384.
25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. http://www.nccn.org/professionals/physician- gls/PDF/hepatobiliary.pdf. Accessed November 21, 2008.
26. Department of Health and Human Services. OPTR/SRTR annual report: transplant data 1997-2006. 2007. http://www.ustransplant.org/annual-reports/ current/113-surv-new-dh.htm. Accessed September 15, 2009.
27. United Network for Organ Sharing. United Network for Organ Sharing data. http://www.unos.org/Data/. Accessed June 5, 2009.
28. Freeman RB Jr, Wiesner RH, Harper A, et al; UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-858.
29. American Liver Tumor Study Group. A Randomized Prospective Multi-Institutional Trial of Orthotopic Liver Transplantation or Partial Hepatic Resection With or Without Adjuvant Chemotherapy for Hepatocellular Carcinoma: Investigators Booklet and Protocol. Richmond, VA: United Network for Organ Sharing; 1998. Policy 3.6.4.4.
30. National Institutes of Health Consensus Development. Liver transplantation. Natl Inst Health Consens Dev Conf Summ. 1983;4(7):15.
31. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15(2):270-285.
32. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease: results in 93 consecutive patients. Ann Surg. 1988;207(4):373-379.
33. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214(3):221-229.
34. Mailey B, Buchberg B, Prendergast C, et al. A disease-based comparison of liver transplantation outcomes. Am Surg. 2009;75(10):901-908.
35. Mazzaferro V, Llovet JM, Miceli R, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35-43.
36. Fink MA, Berry SR, Gow PJ, et al. Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol. 2007;22(1):119-124.
37. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
38. Figueras J, Ibañez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001;7(10):877-883.
39. Ho MC, Wu YM, Hu RH, et al. Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc. 2004;36(8):2291-2292.
40. Xu X, Ke QH, Shao ZX, et al. The value of serum α-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54(2):385-388.
41. Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49(2):223-232.
42. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134(5):1342-1351.